Key Summary Points {#FPar1}
==================

**Why carry out this study***?*Aspirin is recommended as an initial treatment for the secondary prevention of recurrent ischemic stroke in patients with T2DMHowever, clopidogrel might be another choice in case of aspirin intolerence**What was learned from this study?**Clopidogrel monotherapy was neither inferior nor superior to aspirin monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DMHence, clopidogrel or aspirin monotherapy is equally safe in these patients with T2DM

Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) and stroke are two different diseases, but with many aspects in common including dyslipidemia and hypertension \[[@CR1]\]. In fact, due to several factors such as platelet hyperactivity \[[@CR2]\] and occluded vascular arteries \[[@CR3]\], patients with T2DM are more at risk for ischemic stroke \[[@CR4]\]. A recent prospective observational study including over 200 acute stroke patients in a city in Southern Iraq showed diabetes mellitus to be associated with a heavier burden for acute stroke with worse outcomes compared with patients without diabetes \[[@CR1]\]. In the USA, recurrent stroke contributes up to 25% of the annual 800,000 strokes cases \[[@CR5]\]. The rising rate of stroke in patients with T2DM has led to the development of non-invasive techniques such as cerebrovascular intervention for the management of these cases. Cerebrovascular ultrasonography is nowadays being used to detect stroke and select patients for cerebrovascular intervention \[[@CR6]\].

Aspirin is recommended as an initial treatment for the secondary prevention of recurrent ischemic stroke in patients with T2DM \[[@CR7]\]. However, clopidogrel is an oral antiplatelet drug that might be another choice in patients with aspirin intolerance.

In this analysis, we aimed to systematically compare aspirin versus clopidogrel monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM.

Methods {#Sec2}
=======

Data Sources {#Sec3}
------------

Online medical databases including Web of Science, MEDLINE, Cochrane central, EMBASE and <http://www.ClinicalTrials.com> were searched for published articles that satisfied the inclusion and exclusion criteria of this study. Reference lists of suitable articles were also verified for relevant articles.

Search Terms {#Sec4}
------------

Specific search terms were used during the retrieval of English publications:Diabetes mellitus, stroke, aspirin, clopidogrel;Diabetes mellitus, stroke, aspirin, clopidogrel, monotherapy;Diabetes mellitus, stroke, aspirin monotherapy;Diabetes mellitus, stroke, clopidogrel monotherapy;Diabetes mellitus, stroke and anticoagulants;Diabetes mellitus, ischemic stroke, aspirin;Diabetes mellitus, ischemic stroke, clopidogrel;Diabetes mellitus, cerebrovascular attack, aspirin;Diabetes mellitus, cerebrovascular attack, clopidogrel.

Criteria for Inclusion {#Sec5}
----------------------

Studies were included if:They compared outcomes in T2DM patients with previous ischemic stroke who were treated with aspirin versus clopidogrel;They were randomized trials or observation cohorts (prospective/retrospective);They reported clinical outcomes as their end points.

Criteria for Exclusion {#Sec6}
----------------------

Criteria for exclusion were:Studies that did not involve patients with previous ischemic stroke;Studies that did not compare aspirin versus clopidogrel monotherapy;Studies that were literature reviews/meta-analyses/case studies/letters to editors;Duplicated studies.

Data Extraction and Quality Assessment {#Sec7}
--------------------------------------

Data were carefully extracted by seven authors, including the number of participants with T2DM; the number of participants assigned to aspirin and clopidogrel monotherapy, respectively; the number of T2DM participants with ischemic stroke, recurrent stroke, fatal stroke, cerebral hemorrhage and myocardial infarction; the total number of deaths; the baseline characteristics of the participants; the type of study; and the relevant follow-up time periods.

Any disagreement among the authors was further discussed, and a decision was made by the corresponding author.

The quality assessment for the trials was carried out based on the recommendations by the Cochrane Collaboration \[[@CR8]\], and the assessment of the observational studies was carried out by the criteria of the Newcastle-Ottawa Scale (NOS) \[[@CR9]\]. Grades were allotted: grade 'A' implied low risk of bias, grade 'B' was moderate risk of bias, and grade 'C' was high risk of bias.

Outcomes Reported {#Sec8}
-----------------

Recurrent cerebrovascular attack was defined as the occurrence of a new stroke in a patient who already had had a previous stroke.

The following outcomes were assessed during a mean follow-up time period between 1 and 5 years:Recurrent stroke;Fatal stroke;Cerebral hemorrhage;Myocardial infarction (MI);Mortality.

Statistical Analysis {#Sec9}
--------------------

RevMan 5.3 software was used to statistically analyze the data representing each subgroup. Heterogeneity was assessed by two methods: the *Q* statistic test, whereby a *P* value ≤ 0.05 was considered statistically significant, and the *I*^2^ statistic test, whereby heterogeneity increased with a rising *I*^2^ value. In addition, a fixed statistical model (*I*^2^ \< 50%) or a random statistical model (*I*^2^ \> 50%) was used based on this *I*^2^ value. Risk ratios (RRs) with 95% confidence intervals (CIs) were used to represent the results following analysis.

Sensitivity analysis was carried out by a method of exclusion whereby studies were eliminated one by one, and a new analysis was carried out each time to observe any deviation from the main result.

Publication bias was visually observed through funnel plots.

Compliance with Ethical Guidelines {#Sec10}
----------------------------------

This meta-analysis is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec11}
=======

Search Outcomes {#Sec12}
---------------

A total of 945 publications were found through the literature search following the PRISMA guideline \[[@CR10]\]. The abstracts and titles were carefully assessed by the authors, and an initial elimination was carried out whereby 878 publications were eliminated since they were not linked or related to the scope of the current title of this publication. Sixty-seven (67) full-text articles were assessed for eligibility.

A second set of eliminations was carried out but this time following assessment of the full text articles. This elimination was due to publications that:Were literature reviews, systematic reviews, meta-analyses, case studies and letters to editors (9);Did not compare aspirin versus clopidogrel monotherapy (7);Did not involve patients with a history of previous ischemic stroke (8);Aspirin was compared with other antiplatelet monotherapy such as cilostazol (10);Duplicated studies (27).

Finally, only six studies \[[@CR11]--[@CR16]\] were selected for this analysis (Fig. [1](#Fig1){ref-type="fig"}) (Table [1](#Tab1){ref-type="table"}).Fig. 1Flow diagram showing the study selectionTable 1Types of participants, outcomes and follow-up time periodsStudiesTypes of participantsOutcomesMean follow-up time periodCaprie 1996 \[[@CR11]\]T2DM with previous ischemic strokeNon-fatal recurrent stroke, fatal recurrent stroke, non-fatal and fatal MI, death1.91 yearsChi 2018 \[[@CR12]\]T2DM with previous ischemic strokeRecurrent stroke, death1 yearChristiansen 2015 \[[@CR13]\]T2DM with previous ischemic strokeRecurrent ischemic stroke, risk of cerebrovascular bleeding1 yearGe 2019 \[[@CR14]\]T2DM with previous ischemic strokeCerebral micro-bleeding, macroscopic bleeding5 yearsLee 2014 \[[@CR15]\]T2DM with previous ischemic strokeRecurrent stroke, ischemic stroke, intracranial hemorrhage, fatal stroke, MI, mortality1 yearMilionis 2017 \[[@CR16]\]T2DM with previous ischemic strokeMortality, recurrent stroke6 years*T2DM* type 2 diabetes mellitus, *MI* myocardial infarction

Study Features (General) {#Sec13}
------------------------

A total of 9218 participants with T2DM who were previously affected by ischemic stroke were included in this analysis, whereby 4917 were assigned to aspirin and 4301 to clopidogrel, as shown in Table [2](#Tab2){ref-type="table"}.Table 2Main features of the studies included in this meta-analysisStudiesType of studyBias risk grade following assessmentParticipants on ASA monotherapy (*n*)Participants on clopidogrel monotherapy (*n*)Total no. of participants (*n*)Caprie1996Randomized trialB8318081639Chi2018OSB272427135437Christiansen2015Cohort studyB380455835Ge2019Retrospective studyB494998Lee2014Cohort studyB736169905Milionis2017Retrospective studyB197107304Total no. of participants (*n*)----491743019218*OS* observational study, *ASA* aspirin

A methodologic assessment was carried out on the studies. Grade 'B' was allotted to each of the studies showing moderate risk of bias.

Baseline Features of the Participants {#Sec14}
-------------------------------------

Table [3](#Tab3){ref-type="table"} lists the baseline features of the T2DM participants with previous ischemic stroke. Male participants who were on aspirin varied from 47.5% to 66.5%, whereas male patients who were on clopidogrel varied from 49.3% to 74.8%. Mean age of the participants varied between 64.3 and 75.3 years; 42.3% to 79.2% of the participants were hypertensive, 20.3% to 59.8% of the participants suffered from dyslipidemia, and 22.0% to 46.0% of the participants were current smokers.Table 3Baseline features of the participants with type 2 diabetes mellitusStudiesMales (%)Age (years)HBP (%)DYS (%)CS (%)ASA/CloASA/CloASA/CloASA/CloASA/CloCaprie199663.0/64.064.7/64.565.0/65.038.0/37.022.0/22.0Chi201860.2/60.571.8/71.479.2/78.645.0/45.933.3/34.4Christiansen201547.5/49.375.3/68.643.2/42.3----Ge201957.0/54.065.4/64.357.0/53.046.0/43.046.0/42.0Lee201459.7/59.671.1/70.852.0/57.321.8/20.3--Milionis201766.5/74.8--76.6/72.051.8/59.8--*ASA* aspirin, *Clo* clopidogrel, *HBP* high blood pressure, *DYS* dyslipidemia, *CS* current smoker

Main Results of this Analysis {#Sec15}
-----------------------------

This current analysis showed that there was no significant difference in recurrent stroke (RR: 0.79, 95% CI: 0.61--1.02; *P* = 0.07) observed with aspirin versus clopidogrel monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM as shown in Fig. [2](#Fig2){ref-type="fig"}. Our analysis also showed that the risk of fatal stroke (RR: 0.88, 95% CI: 0.39--1.98; *P* = 0.76), cerebral hemorrhage (RR: 0.65, 95% CI: 0.38--1.11; *P* = 0.12), MI (RR: 0.88, 95% CI: 0.43--1.79; *P* = 0.71) and mortality (RR: 1.07, 95% CI: 0.90--1.27; *P* = 0.44) were also similar with aspirin versus clopidogrel monotherapy in these patients with T2DM as shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 2Recurrent stroke observed in T2DM patients on aspirin versus clopidogrel monotherapyFig. 3Other clinical outcomes observed in T2DM patients on aspirin versus clopidogrel monotherapy

The results have been summarized in Table [4](#Tab4){ref-type="table"}.Table 4Summarizing the results of this analysis involving participants with T2DM previously affected by strokeOutcomesRR with 95% CI*P* value*I*^2^ value (%)Recurrent stroke0.79 \[0.61--1.02\]0.0758Fatal stroke0.88 \[0.39--1.98\]0.760Cerebral hemorrhage0.65 \[0.38--1.11\]0.120Myocardial infarction0.88 \[0.43--1.79\]0.710Death1.07 \[0.90--1.27\]0.4449*RRs* risk ratios, *CIs* confidence intervals

Consistent results were obtained throughout when sensitivity analysis was carried out.

Visual assessment of the funnel plot also showed minimal evidence of publication bias across the studies that were involved in assessing the cerebrovascular and other clinical outcomes among these patients with T2DM as shown in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4Funnel plot representing publication bias

Discussion {#Sec16}
==========

This current analysis showed that in patients with T2DM, aspirin or clopidogrel monotherapy was equally effective and safe for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke. There was no significant difference in recurrent stroke, fatal stroke, cerebral hemorrhage, myocardial infarction and mortality when either aspirin or clopidogrel monotherapy was used in these patients with T2DM.

The Study of Cardiovascular Events in Diabetes (ASCEND) randomized trial demonstrated that aspirin monotherapy in patients with T2DM could prevent serious vascular events \[[@CR17]\]. Among the 15,480 participants, serious vascular events occurred more in the placebo compared with the aspirin group. However, major bleeding was also observed with the use of aspirin in these patients compared with those who did not use antiplatelet medications.

Apart from clopidogrel, aspirin monotherapy has also been compared with other anticoagulants in patients with recurrent stroke. For example, in the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with the TP receptor antagonist teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study, the baseline features of the population were described \[[@CR7]\].

Ten-year survival data from the Athens Stroke Outcome Project \[[@CR16]\] showed clopidogrel monotherapy to be more favorable compared with aspirin monotherapy for the prevention of recurrent stroke in patients with T2DM. Among 197 participants with T2DM who were treated by aspirin and 107 participants who were treated with clopidogrel, recurrent stroke occurred only in 11.2% of the participants, whereas 19.7% of the participants on aspirin suffered recurrent stroke.

Antiplatelet drugs in patients with T2DM and in patients with T2DM who have undergone cerebrovascular intervention are vital in this era. Further research should be carried out on this aspect to have a better choice of antiplatelet agent in such patients without any increased risk of bleeding.

Limitations {#Sec17}
-----------

Several limitations were observed in this study. First, the total number of participants might not be sufficiently large to draw a strong and powerful conclusion. The total number of studies selected for this analysis was limited since there have seldom been research articles based on aspirin versus clopidogrel monotherapy in T2DM participants with previous cerebrovascular attack. Hence, subgroups assessing fatal stroke and MI involved only two studies. The other studies did not report these two outcomes and hence could not be included during subgroup analyses for these specific outcomes. Several other important outcomes and adverse drug events including gastrointestinal bleeding, abdominal pain, melena and other bleeding tendencies could not be assessed since they were not reported in the original studies. Moreover, another limitation of this analysis might be the fact that data from randomized trials and observational studies were combined and analyzed. This might have affected the result of this analysis. However, the total number of studies were limited, and separating randomized trials and observational cohorts and carrying out an analysis would not have been possible.

Conclusions {#Sec18}
===========

Clopidogrel monotherapy was neither inferior nor superior to aspirin monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM. Hence, clopidogrel or aspirin monotherapy is equally safe and effective in these patients with T2DM.
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